For the Inventor, By the Inventor

Enter assignee name

San Carlos, CA, United States of America

Chemocentryx, Inc.

USPTO Granted Patents = 215

CIPO Patents = 8

EPO Patents = 59

Trademarks = 5

Forward Citations = 1,361

Loading Chart...

Loading Chart...

113 inventors (with patents filed for the assignee):

Penglie Zhang (106 out of 125 patents)

Sreenivas Punna (66 out of 66 patents)

Yibin Zeng (62 out of 66 patents)

4. Jay Patrick Powers (54 out of 123 patents)

5. Ju Yang (50 out of 54 patents)

6. Venkat Reddy Mali (49 out of 59 patents)

7. Rajinder Paul Singh (46 out of 369 patents)

8. Pingchen Fan (45 out of 61 patents)

9. Manmohan Reddy Leleti (41 out of 69 patents)

10. Hiroko Tanaka (41 out of 47 patents)

11. Christopher W Lange (40 out of 47 patents)

12. Viengkham Malathong (39 out of 51 patents)

13. Thomas J Schall (39 out of 50 patents)

14. Rebecca M Lui (38 out of 41 patents)

15. Antoni Krasinski (35 out of 36 patents)

Core Competencies:

C5a Antagonists

CCR2 Modulators

PD-L1 Inhibitors

Chemokine Receptors

Immunomodulator Compounds

Focal Segmental Glomerulosclerosis

Cancer Treatment

Inflammatory Bowel Disease

Tumor Burden Reduction

Hidradenitis Suppurativa

C3 Glomerulopathy

Combination Therapy

215 patents: Sort by Forward Citations

1. 12497383 - Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases (2025-12-16),

2. 12350263 - Dosing and effect of C5a antagonist with ANCA-associated vasculitis (2025-07-08),

3. 12268675 - Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors (2025-04-08),

4. 12194032 - Method of treating focal segmental glomerulosclerosis (2025-01-14),

5. 12139475 - 2-oxindole compounds (2024-11-12),

6. 12054484 - Substituted tetrahydropyrans as CCR2 modulators (2024-08-06),

7. 12012403 - Aryl sulfonyl compounds as CCR6 inhibitors (2024-06-18),

8. 12011439 - Combination therapy using C—C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors (2024-06-18),

9. 11986466 - Methods of treating solid tumors with CCR2 antagonists (2024-05-21),

10. 11951214 - Capsule formulations (2024-04-09),

11. 11945805 - Inhibitors of CXCR2 (2024-04-02),

12. 11890276 - Methods of treating pancreatic cancer (2024-02-06),

13. 11884654 - Substituted anilines as CCR(4) antagonists (2024-01-30),

14. 11883391 - Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodies (2024-01-30),

15. 11872217 - Indanes as PD-L1 inhibitors (2024-01-16),

ChemoCentryx is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer. They are dedicated to transforming the lives of patients through innovative science and targeted therapies. With a deep understanding of the immune system and its role in diseases, ChemoCentryx aims to provide breakthrough treatments that can make a meaningful difference in the lives of patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

215 Patents

#1 in San Carlos, CA

#428 in California

#1,874 in US

#3,860 in the World

San Carlos, CA, United States of America

Chemocentryx, Inc.

Forward Citations = 1,361

113 inventors:

Penglie Zhang (106 out of 125 patents)

Sreenivas Punna (66 out of 66 patents)

Yibin Zeng (62 out of 66 patents)

4. Jay Patrick Powers (54 out of 123 patents)

5. Ju Yang (50 out of 54 patents)

Please report any incorrect information to support@idiyas.com

Loading…